SM
CERE

SG3 Management’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

SG3 Management’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-30,000
Closed -$946K – 182
2022
Q4 		$946K Buy
+30,000
New +$847K 0.14% 88
2022
Q3 		– Sell
-10,000
Closed -$264K – 475
2022
Q2 		$264K Sell
10,000
-25,000
-71% -$710K 0.03% 257
2022
Q1 		$1.23M Buy
+35,000
New +$1.02M 0.03% 410

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

SG3 Management's CERE Position: Q3 2022 in Review

SG3 Management sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2022, closing a stake of 10,000 shares — an estimated $298K sold.

SG3 Management first reported a position in CERE in Q2 2022 and held it in 1 quarter. The position peaked at $264K in Q2 2022. 114 funds tracked by Wall St. Rank hold CERE as of Q3 2022.

  • SG3 Management reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
  • SG3 Management sold 10,000 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2022, an estimated $298K.
  • SG3 Management first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q2 2022 and held it in 1 quarter.
  • SG3 Management's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $264K in Q2 2022.
  • 114 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2022.

Based on SG3 Management's 13F filing for Q3 2022, filed 14 Nov 2022.